Clinical Trial

A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to support the development of remibrutinib dosing recommendations for patients with impaired renal function.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-06-19; most recent amendment 2026-03-26.
Status change: Recruiting → Completed 2026-01-28
Status change: Not Yet Recruiting → Recruiting 2025-08-28
Trial Details
NCT Number NCT07032272
Lead Sponsor Novartis Pharmaceuticals
Conditions Autoimmune and Chronic Inflammatory Diseases
Enrollment 16 participants
Start Date 2025-07-23
Primary Completion 2025-10-12 (estimated)
Study Completion 2025-10-14 (estimated)
Updated on ClinicalTrials.gov 2026-03-30